The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase
IMiD 诱导 CRL4CRBN 泛素 E3 连接酶招募新底物的分子基础
基本信息
- 批准号:10627797
- 负责人:
- 金额:$ 38.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-03-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:8p11AcuteAddressAffectAllelesBindingBiologicalBiological ModelsBirthC2H2 Zinc FingerCellsCharacteristicsChemicalsChemistryChildChimeric ProteinsClinicClinicalComplexCongenital AbnormalityDataDevelopmentDysmyelopoietic SyndromesEmbryoEngineeringEukaryotaExplosionFDA approvedFGFR1 geneFamilyFutureGluesGoalsGrantHematologic NeoplasmsHumanHuman GeneticsKnock-inLeadLearningLigaseMalignant NeoplasmsMarketingMass Spectrum AnalysisMeasurementMediatingMemoryMissense MutationModalityMolecularMorning SicknessMultiple MyelomaMusMutationMyeloproliferative diseaseOncogenesOncogenicPharmaceutical PreparationsPharmacotherapyPhenocopyPhocomeliaPhysiologicalPlayPregnancyPregnant WomenProteinsProteomicsRBX1 geneRecording of previous eventsResearchResourcesRoleSelf MutilationStructureSyndromeTechnologyTeratogenic effectsTeratogensTestingThalidomideTherapeuticTherapeutic EffectTimeToxicity TestsType 1 Duane Retraction SyndromeWithdrawalWorkZinc Fingersanalogcancer therapycasein kinase Ichromosome 5q lossclinical developmentconsanguineous familyeffective therapygain of functionhuman embryonic stem cellimmune modulating agentsin vivoin vivo Modelinhibitorinsightlenalidomideloss of functionmembermouse modelneurodevelopmentnew therapeutic targetnovelnovel therapeuticsphosphoric diester hydrolasepomalidomidepreclinical developmentpreventprotein degradationrational designrecruitresponsescaffoldsevere intellectual disabilitysmall molecule therapeuticsstandard of caretargeted treatmenttooltranscription factorubiquitin ligaseubiquitin-protein ligase
项目摘要
Project Summary
Developed in the 1950s, Thalidomide was used to treat morning sickness in the early stages of pregnancy, which
led to the birth of thousands of children with severe birth defects and subsequent withdrawal from the market.
Today, thalidomide and its analogs lenalidomide and pomalidomide (collectively known as IMiDs) are FDA
approved drugs and effective treatments for hematologic malignancies such as multiple myeloma and Del(5q)
MDS. But despite over 60 years of research, the mechanistic understanding of how these molecules cause the
characteristic birth defects is only just beginning to unravel. Due to the wide use of IMiDs in the clinic, and the
recent explosion in the development of targeted protein degradation therapies based often on the original
thalidomide scaffold, it is more critical than ever that we understand the full range of potential activities that IMiDs
provoke. Here, we propose to explore the broad range of potential activities that result from these IMiD-like
molecules binding to the E3 ligase CUL4-RBX1-DDB1-CRBN (CRL4CRBN) and redirecting its activity towards
different targets. Specifically, in aim 1, we will engineer an in vivo mouse model of Sall4 degradation to dissect
how thalidomide-mediated degradation of Sall4 leads to teratogenicity. We will do this through a combination of
expression analyses and developmental measurements to assess the affect that IMiD molecules have on the
developing embryo. This will not only enable the study of the mechanism of teratogenic activity of these drugs
but will also provide a critical model system for testing the toxicity of current and future versions of these
molecules. Not only do these molecules induce a gain-of-function to target new proteins, but they also induce a
loss-of-function and in aim 2, we propose to use novel mass spectrometry-based proteomics technology in
combination with potent and selective tool compounds to explore the biological consequences of blocking CRBN
activity. We have previously shown that we can expand the scope of IMiD targets through rational design of new
IMiD-like molecules capable of degrading new proteins related to known targets. In aim 3, we propose to expand
the target scope even further by developing novel chemistry to target structurally diverse proteins that have a
strong therapeutic rationale, thus providing proof-of-concept for target expansion and providing chemical leads
for new therapeutic targets. The overarching goal of this grant is to explore the full range of potential activities of
the widely utilized CRL4CRBN ligase by identifying and exploring the mechanistic consequences of degrading its
physiological and IMiD-induced targets, as well as seeking to expand its target space into currently undruggable
territories.
项目摘要
开发于20世纪50年代的沙利度胺用于治疗怀孕早期的晨吐,
导致数千名患有严重出生缺陷的儿童出生,随后退出市场。
今天,沙利度胺及其类似物来那度胺和泊马度胺(统称为IMiDS)是FDA
多发性骨髓瘤和DEL(5q)等恶性血液病的批准药物和有效治疗
MDS。但是,尽管经过60多年的研究,对这些分子如何导致
典型的出生缺陷才刚刚开始解体。由于IMIDS在临床上的广泛使用,以及
最近,靶向蛋白质降解疗法的发展呈爆炸性增长,这些疗法往往基于原始的
沙利度胺支架,比以往任何时候都更重要的是,我们必须全面了解IMIDS的潜在活动范围
挑衅。在这里,我们建议探索这些类似IMIDD的潜在活动的广泛范围
与E3连接酶CUL4-RBX1-DDB1-CRBN(CRL4CRBN)结合的分子并将其活性重定向为
不同的目标。具体地说,在目标1中,我们将设计一个体内Sall4降解的小鼠模型来解剖
沙利度胺介导的Sall4降解如何导致致畸。我们将通过以下组合来实现这一点
表达分析和发育测量以评估IMiD分子对
发育中的胚胎。这不仅有助于研究这些药物的致畸作用机制。
但也将提供一个关键的模型系统,用于测试当前和未来版本的这些
分子。这些分子不仅诱导功能增强以靶向新的蛋白质,而且它们还诱导
在目标2中,我们建议将新的基于质谱学的蛋白质组学技术用于
结合有效和选择性的工具化合物探索阻断CRBN的生物学后果
活动。我们之前已经证明,我们可以通过合理设计新的
能够降解与已知靶标相关的新蛋白质的IMID样分子。在目标3中,我们建议扩大
通过发展新的化学来靶向具有结构多样性的蛋白质,靶向范围进一步扩大
强大的治疗理论基础,从而为目标扩展提供概念验证,并提供化学先导
寻找新的治疗靶点。这笔赠款的首要目标是探索各种潜在的活动
广泛使用的CRL4CRBN连接酶通过识别和探索其降解的机制后果
生理和IMiD诱导的靶点,以及寻求将其靶点空间扩大到目前无法下药的
领地。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eric Sebastian Fischer其他文献
Eric Sebastian Fischer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eric Sebastian Fischer', 18)}}的其他基金
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs
开发适用于 HDAC 的小分子降解剂的通用化学蛋白质组学筛选平台
- 批准号:
10442847 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别:
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs
开发适用于 HDAC 的小分子降解剂的通用化学蛋白质组学筛选平台
- 批准号:
10640286 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别:
Degrading therapeutically important kinases using small molecules
使用小分子降解治疗上重要的激酶
- 批准号:
10547760 - 财政年份:2021
- 资助金额:
$ 38.88万 - 项目类别:
Degrading therapeutically important kinases using small molecules
使用小分子降解治疗上重要的激酶
- 批准号:
10424788 - 财政年份:2021
- 资助金额:
$ 38.88万 - 项目类别:
Degrading therapeutically important kinases using small molecules
使用小分子降解治疗上重要的激酶
- 批准号:
10311055 - 财政年份:2021
- 资助金额:
$ 38.88万 - 项目类别:
Degrading therapeutically important kinases using small molecules
使用小分子降解治疗上重要的激酶
- 批准号:
10066259 - 财政年份:2018
- 资助金额:
$ 38.88万 - 项目类别:
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.
IMiD 的分子基础诱导 CRL4CRBN 泛素 E3 连接酶招募新底物。
- 批准号:
10091409 - 财政年份:2017
- 资助金额:
$ 38.88万 - 项目类别:
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase
IMiD 诱导 CRL4CRBN 泛素 E3 连接酶招募新底物的分子基础
- 批准号:
10374974 - 财政年份:2017
- 资助金额:
$ 38.88万 - 项目类别:
The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.
IMiD 的分子基础诱导 CRL4CRBN 泛素 E3 连接酶招募新底物。
- 批准号:
9899745 - 财政年份:2017
- 资助金额:
$ 38.88万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 38.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
Operating Grants